Zobrazeno 1 - 10
of 101
pro vyhledávání: '"I Diaz-Padilla"'
Autor:
Fei Su, Mafalda Oliveira, Yu Han, Luc Dirix, Javier Cortes, Aditya Bardia, Mariana Chavez-MacGregor, Karen Rodriguez Lorenc, Mario Campone, Wei He, Brigette B.Y. Ma, Becker Hewes, Tanay S. Samant, Shanu Modi, Priya Deshpande, Amy Weise, I Diaz-Padilla
Publikováno v:
Clinical Cancer Research. 26:6417-6428
Purpose: Report results of the phase Ib dose-escalation/expansion study of triplet therapy with cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor (ribociclib), mTOR inhibitor (everolimus), and endocrine therapy (exemestane). Patients and Methods: P
Autor:
Paul Wheatley-Price, Saúl Campos-Gómez, I Diaz-Padilla, Y-H Im, Gareth Hughes, V Srimuninnimit, Aditya Bardia, Marco Colleoni, Faye Su, Debu Tripathy, KH Jung, M. Miller, David Taylor, Sherko Kümmel
Publikováno v:
Cancer Research. 79:PD2-08
Background: In the MONALEESA-7 study (NCT02278120), ribociclib (RIB) + a non-steroidal aromatase inhibitor (NSAI)/tamoxifen (TAM) + goserelin (GOS) significantly improved progression-free survival (PFS) vs placebo (PBO) + NSAI/TAM + GOS in premenopau
Autor:
Debu Tripathy, S-A Im, Aditya Bardia, Francisco J. Esteva, M. Campone, S Chia, W Bao, O Kong, Andrew T. Chan, D. A. Yardley, I Diaz-Padilla, H. A. Burris, K Rodriguez Lorenc
Publikováno v:
Cancer Research. 79:P6-18
Background: In Phase III trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + various endocrine therapy (ET) partners has demonstrated significantly prolonged progression-free survival vs placebo (PBO) + ET in patients (pts) with hormone
Autor:
J. Alam, Patrick Neven, Joohyuk Sohn, Thomas Bachelot, I Diaz-Padilla, M. Martin, Saúl Campos-Gómez, O Kong, Gabe S. Sonke, Aditya Bardia, Andrew T. Chan, M. Miller, Lowell L. Hart, JT Beck
Publikováno v:
Cancer Research. 79:P6-18
Background: In the MONALEESA (ML) trials, addition of ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) to endocrine therapy (ET) prolonged progression-free survival (PFS) in patients (pts) with hormone receptor-positive (HR+), HER2-negative (H
Autor:
Debu Tripathy, S Hurvitz, Fabio Franke, Y-S Lu, Fatima Cardoso, I Diaz-Padilla, FM Cruz, A. Gaur, Saúl Campos-Gómez, Aditya Bardia, Paul Wheatley-Price, O Kong, M. Miller, Roberto Hegg
Publikováno v:
Cancer Research. 79:P6-18
Background: Younger patients (pts) with breast cancer may experience more aggressive disease and are more likely to die from their cancer vs older pts. In the Phase III MONALEESA-7 study (NCT02278120), the addition of ribociclib (RIB; cyclin-dependen
Autor:
W Bao, S Chia, DJ Slamon, Gabriel N. Hortobagyi, S-A Im, O Kong, Francisco J. Esteva, S Hurvitz, Debu Tripathy, D. A. Yardley, Andrew T. Chan, I Diaz-Padilla, K Rodriguez Lorenc
Publikováno v:
Cancer Research. 79:P6-18
Background: In three separate Phase III randomized, placebo-controlled trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + various endocrine therapy (ET) partners prolonged progression-free survival (PFS) vs placebo (PBO) + ET in patien
Autor:
Francisco J. Esteva, Andrew T. Chan, O Kong, Paul Wheatley-Price, Arnd Nusch, Y-S Yap, DJ Slamon, H. A. Burris, K Rodriguez Lorenc, D. A. Yardley, A Gaur, I Diaz-Padilla, Thomas Bachelot, Gabe S. Sonke
Publikováno v:
Cancer Research. 79:P6-18
Background: Patients (pts) with advanced breast cancer (ABC) who present with visceral metastases (mets) have a poorer prognosis vs pts with non-visceral disease. In the Phase III MONALEESA (ML) trials, ribociclib (RIB) + endocrine therapy (ET) prolo
Autor:
Keun Seok Lee, Louis W.C. Chow, Joohyuk Sohn, Debu Tripathy, Seock-Ah Im, Saúl Campos-Gómez, Mei Ching Liu, Paul Wheatley-Price, Aditya Bardia, K Govind Babu, Yen-Shen Lu, Rafael Villanueva Vazquez, Fabio Franke, Sara A. Hurvitz, Samit Hirawat, C. Germa, Gary Carlson, Kyung Hae Jung, I Diaz-Padilla, Young-Hyuck Im, Sherko Kuemmel, Nadia Harbeck, Gareth Hughes, Nagi S. El-Saghir, Michelino De Laurentiis, Marco Colleoni
Publikováno v:
The Lancet Oncology. 19:904-915
Background: In MONALEESA-2, ribociclib plus letrozole showed improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast canc
Autor:
Jung Ho Sohn, Aditya Bardia, Gary Carlson, Lwc Chow, Gareth Hughes, R. Villanueva Vázquez, S Hirawat, Y-S Lu, Fabio Franke, Marco Colleoni, Debu Tripathy, Nadia Harbeck, KS Lee, S Hurvitz, C. Germa, Saúl Campos-Gómez, Kyung Hwa Jung, S-A Im, I Diaz-Padilla
Publikováno v:
Cancer Research. 78:GS2-05
Background:Endocrine therapy (ET) with ovarian function suppression is an established first-line treatment for pre- and peri-menopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced b
Autor:
Andrew Bayley, Nancy Read, L.L. Siu, Kelvin K. W. Chan, Soo Chin, Eric X. Chen, I. Diaz-Padilla, Eric Winquist, John Waldron, Albiruni Ryan Abdul Razak, Andrew Hope, Lisa Wang, John Kim, David A. Palma, M. Hossain, Herbert H. Loong
Publikováno v:
European Journal of Cancer. 50:2263-2270
Induction chemotherapy followed by concurrent chemoradiation (CRT) (sequential therapy) has been evaluated in the treatment of locoregionally-advanced squamous cell cancer of the head and neck (LA-SCCHN), with docetaxel, cisplatin (P) and 5-flurourac